Why is Marksans Pharma falling/rising?

As of 25-Aug, Marksans Pharma Ltd's stock price is currently at 177.65, reflecting a decrease of 2.15, or 1.2%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 3.69% during this period. Today's trading saw the stock touch an intraday low of Rs 175.1, and it is trading below all key moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume decreasing by 43.79% compared to the five-day average. Over the past month, the stock has experienced a substantial decline of 22.08%, while its year-to-date performance shows a staggering drop of 40.03%. The company's recent financial results have also been disappointing, with a notable decline in profit before tax and profit after tax compared to previous quarters, contributing to a negative sentiment around the stock.
In the broader market context, Marksans Pharma's performance has been significantly worse than the benchmark, as it has underperformed the Sensex, which has gained 0.45% over the past week, while Marksans has dropped 3.50%. The company's long-term growth prospects appear poor, with an annual operating profit decline of 0.29% over the last five years, and a high price-to-earnings growth (PEG) ratio of 4.7 suggests that the stock may be overvalued relative to its earnings growth. Despite having high management efficiency and institutional holdings, the negative financial results and the stock's substantial underperformance compared to the market indicate a lack of investor confidence, leading to the current downward price movement.